Pros | - | 5Y returns in the top 25% of the category. 3Y returns in the top 25% of the category. Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | - | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 4 Years | 7 Years | ||
Fund Size | 233 Cr | 6437 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 1.03% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 44 | 44 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.96%) Divi's Laboratories Ltd (8.97%) Apollo Hospitals Enterprise Ltd (6.35%) Max Healthcare Institute Ltd Ordinary Shares (5.71%) Torrent Pharmaceuticals Ltd (4.59%) | Sun Pharmaceuticals Industries Ltd (11.88%) Dr Reddy's Laboratories Ltd (9.42%) Divi's Laboratories Ltd (8.5%) Aurobindo Pharma Ltd (7.62%) Cipla Ltd (6.61%) | ||
No of Sectors | 4 | 3 | ||
Top 3 Sectors | Health (94.75%) Basic Materials (2.92%) Financial Services (1.27%) | Health (97.59%) Basic Materials (1.21%) Financial Services (1.2%) | ||
Equity % | 98.3% | 97.1% | ||
Debt % | - | - | ||
P/E | - | - | ||
P/B | - | - | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -2.28% | -0.32% | ||
3-Month Return | -0.78% | 1.14% | ||
6-Month Return | 1.68% | 5.54% | ||
1-Year Return | -5.47% | 4.63% | ||
3-Year Return | 20.58% | 27.76% | ||
5-Year Return | - | 19.76% |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Rohan Korde,Dhimant Shah | Dharmesh Kakkad,Sharmila D’mello |